15 - References

References

Prescribing in children and adolescents CHAPTER 5 References

1. Pina-­Camacho L, et al. Autism spectrum disorder and schizophrenia: boundaries and uncertainties. BJPsych Advances 2016; 22:­316–­324.
2. Hayes D, et al. Dilemmas in the treatment of early-­onset first-­episode psychosis. Ther Adv Psychopharmacol 2018; 8:­231–­239.
3. Kumra S, et al. Efficacy and tolerability of second-­generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull 2008; 34:­60–­71.
4. Singappuli P, et al. Antipsychotic long-­term treatment in children and young people: a systematic review and meta-­analysis of efficacy and tolerability across mental health and neurodevelopmental conditions. CNS Spectr 2022; 27:­570–­587.
5. Lee ES, et al. Psychopharmacologic treatment of schizophrenia in adolescents and children. Child Adolesc Psychiatr Clin N Am 2020; 29:­183–­210.
6. Connor DF, et al. Neuroleptic-­related dyskinesias in children and adolescents. J Clin Psychiatry 2001; 62:­967–­974.
7. Campbell M, et al. Neuroleptic-­related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry 1997; 36:­835–­843.
8. Sikich L, et al. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-­blind, randomized, 8-­week trial. Neuropsychopharmacology 2004; 29:­133–­145.
9. Sikich L, et al. Double-­blind comparison of first-­ and second-­generation antipsychotics in early-­onset schizophrenia and schizo-­affective disorder: findings from the treatment of early-­onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 2008; 165:­1420–­1431.
10. Kryzhanovskaya L, et  al. Olanzapine versus placebo in adolescents with schizophrenia: a 6-­week, randomized, double-­blind, placebo-­ controlled trial. J Am Acad Child Adolesc Psychiatry 2009; 48:­60–­70.
11. Haas M, et al. A 6-­week, randomized, double-­blind, placebo-­controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol 2009; 19:­611–­621.
12. Haas M, et al. Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-­blind study. Br J Psychiatry 2009; 194:­158–­164.
13. Findling RL, et al. A multiple-­center, randomized, double-­blind, placebo-­controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 2008; 165:­1432–­1441.
14. Pagsberg AK, et al. Quetiapine extended release versus aripiprazole in children and adolescents with first-­episode psychosis: the multicentre, double-­blind, randomised tolerability and efficacy of antipsychotics (TEA) trial. Lancet Psychiatry 2017; 4:­605–­618.
15. Findling RL, et al. Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-­week, double-­blind, placebo-­ controlled trial. J Child Adolesc Psychopharmacol 2012; 22:­327–­342.
16. Singh J, et  al. A randomized, double-­blind study of paliperidone extended-­release in treatment of acute schizophrenia in adolescents. Biol Psychiatry 2011; 70:­1179–­1187.
17. Arango C, et al. Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-­analysis. Eur Child Adolesc Psychiatry 2019; 29:­1195–­1205.
18. Pagsberg AK, et al. Acute antipsychotic treatment of children and adolescents with schizophrenia-­spectrum disorders: a systematic review and network meta-­analysis. J Am Acad Child Adolesc Psychiatry 2017; 56:­191–­202.
19. Lopez-­Morinigo JD, et al. Pharmacological treatment of early-­onset schizophrenia: a critical review, evidence-­based clinical guidance and unmet needs. Pharmacopsychiatry 2022; 55:­233–­245.
20. Jensen KG, et al. Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with first-­episode psychosis: results from the TEA trial. Psychopharmacology (Berl) 2018; 235:­681–­693.
21. Goldman R, et al. Efficacy and safety of lurasidone in adolescents with schizophrenia: a 6-­week, randomized placebo-­controlled study. J Child Adolesc Psychopharmacol 2017; 27:­516–­525.
22. Baeza I, et al. What role for long-­acting injectable antipsychotics in managing schizophrenia spectrum disorders in children and adolescents? A systematic review. Paediatr Drugs 2023; 25:­135–­149.
23. Sunshine A, et al. Practitioner review: psychosis in children and adolescents. J Child Psychol Psychiatry 2023; 64:­980–­988.
24. Correll CU, et al. Metformin add-­on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial. World Psychiatry 2020; 19:­69–­80.
25. Kumra S, et al. Childhood-­onset schizophrenia. A double-­blind clozapine-­haloperidol comparison. Arch Gen Psychiatry 1996; 53:­1090–­1097.
26. Shaw P, et al. Childhood-­onset schizophrenia: a double-­blind, randomized clozapine-­olanzapine comparison. Arch Gen Psychiatry 2006; 63:­721–­730.
27. Kumra S, et al. Clozapine and ‘high-­dose’ olanzapine in refractory early-­onset schizophrenia: a 12-­week randomized and double-­blind comparison. Biol Psychiatry 2008; 63:­524–­529.
28. Schneider C, et al. Systematic review of the efficacy and tolerability of clozapine in the treatment of youth with early onset schizophrenia. Eur Psychiatry 2014; 29:­1–­10.
29. Adnan M, et al. Clozapine for management of childhood and adolescent-­onset schizophrenia: a systematic review and meta-­analysis. J Child Adolesc Psychopharmacol 2022; 32:­2–­11.
30. Agid O, et al. An algorithm-­based approach to first-­episode schizophrenia: response rates over 3 prospective antipsychotic trials with a ­retrospective data analysis. J Clin Psychiatry 2011; 72:­1439–­1444.
31. National Institute for Health and Care Excellence. Psychosis and schizophrenia in children and young people: recognition and management. Clinical Guidance [CG155]. 2013 (last updated October 2016, last checked October 2023); https://www.nice.org.uk/guidance/cg155.
32. Catalan A, et al. Annual research review: prevention of psychosis in ­adolescents –­ systematic review and meta-­analysis of advances in detection, prognosis and intervention. J Child Psychol Psychiatry 2021; 62:­657–­673.
33. Lång U, et al. Systematic review and meta-­analysis: psychosis risk in children and adolescents with an at-­risk mental state. J Am Acad Child Adolesc Psychiatry 2022; 61:­615–­625.